{"id":5266,"date":"2025-11-30T17:45:09","date_gmt":"2025-11-30T14:45:09","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5266"},"modified":"2025-12-01T09:37:23","modified_gmt":"2025-12-01T06:37:23","slug":"del-zota-clinical-trial-begins-in-the-us-nct07250737","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/del-zota-clinical-trial-begins-in-the-us-nct07250737\/","title":{"rendered":"ABD'de Ekzon 44 Atlamaya Uygun DMD Mutasyonlar\u0131na Sahip Kat\u0131l\u0131mc\u0131larda Del-Zota Klinik \u00c7al\u0131\u015fmas\u0131 Ba\u015flad\u0131"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Avidity Biosciences announced the commencement of clinical trials [NCT07250737] to provide access to delpacibart zotadirsen (AOC 1044) to eligible patients diagnosed with DMD mutations amenable to exon 44 skipping under its Managed Access Program. &gt;&gt; Read More: <a href=\"https:\/\/dmdwarrior.com\/avidity-biosciences-announces-u-s-managed-access-program-map-for-investigational-therapy-del-zota-in-dmd44\/\" target=\"_blank\" rel=\"noreferrer noopener\">Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota (Exon 44 Skipping)<\/a><\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table of Contents<\/h2><nav><ul><li><a href=\"#what-is-del-zota-exon-44-skipping-therapy\">What is Del-Zota Exon 44 Skipping Therapy<\/a><\/li><li><a href=\"#bbm-d-101-phase-1-2-participation-criteria\">Del-Zota Phase 1 Participation Criteria<\/a><\/li><li><a href=\"#how-to-participate-in-the-wve-n-531-clinical-trial\">How to Participate in the Del-Zota Clinical Trial<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-del-zota-exon-44-skipping-therapy\">What is Del-Zota Exon 44 Skipping Therapy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Del-zota is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene to enable dystrophin production in people living with Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Read More<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/mutations-and-deletions-amenable-to-exon-44-skipping-therapies-dmd\/\" data-type=\"post\" data-id=\"4192\">Mutations and Deletions Amenable to Exon 44 Skipping Therapies for Duchenne Muscular Dystrophy<\/a><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"968\" height=\"1024\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping-968x1024.jpg\" alt=\"Mutations and Deletions Amenable to Exon 44 Skipping Therapies for Duchenne Muscular Dystrophy\" class=\"wp-image-5275\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping-968x1024.jpg 968w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping-284x300.jpg 284w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping-768x813.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping-1452x1536.jpg 1452w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping-11x12.jpg 11w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping-397x420.jpg 397w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping-150x159.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping-300x317.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping-696x737.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping-1068x1130.jpg 1068w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/11\/Deletions-Amenable-to-Exon-44-Skipping.jpg 1890w\" sizes=\"auto, (max-width: 968px) 100vw, 968px\" \/><figcaption class=\"wp-element-caption\"><strong>Deletions Amenable to Exon 44 Skipping Therapies for Duchenne Muscular Dystrophy<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bbm-d-101-phase-1-2-participation-criteria\">Del-Zota Phase 1 Participation Criteria<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">People must fulfill the inclusion requirements in order to be eligible. If a person has another ailment or is undergoing treatment that could prevent them from receiving exon skipping therapy, they might not be able to participate. The complete set of inclusion and exclusion criteria can be found by clicking on this study link \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07250737\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07250737<\/a> \u2013.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-to-participate-in-the-wve-n-531-clinical-trial\">How to Participate in the Del-Zota Clinical Trial<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">To participate in the Del-Zota Exon 44 Skipping Clinical Trial, you can use the contact information below.&nbsp;<strong>Learn More<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/how-to-participate-in-clinical-trials-for-duchenne\/\" target=\"_blank\" rel=\"noreferrer noopener\">How to Participate in Clinical Trials for Duchenne (DMD)?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Name<\/strong>: Clinigen Customer Service<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Phone Number<\/strong>: 1 877 768 4303<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Email<\/strong>:&nbsp;MedicineAccess@clinigengroup.com<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Read More<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Clinical Trials for Duchenne (List of All Researches)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Avidity Biosciences announced the commencement of clinical trials [NCT07250737] to provide access to delpacibart zotadirsen (AOC 1044) to eligible patients diagnosed with DMD mutations amenable to exon 44 skipping under its Managed Access Program. &gt;&gt; Read More: Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota (Exon 44 Skipping) What is Del-Zota [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5268,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[459,126,137,298,397,129,141,127,246],"class_list":["post-5266","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-aoc-1044","tag-avidity-biosciences","tag-clinical-trial","tag-del-zota","tag-delpacibart-zotadirsen","tag-dmd44","tag-exon-44","tag-exon-44-skipping","tag-exon-44-skipping-therapies"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=5266"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5266\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/5268"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=5266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=5266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=5266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}